• Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (PubMed=23447416; PubMed=23615946).
  
• Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (PubMed=23615946).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=14518029; PubMed=23615946; Cosmic-CLP; DepMap).
  

PubMed=11317522
Korenchuk S., Lehr J.E., McLean L., Lee Y.-G., Whitney S., Vessella R.L., Lin D.L., Pienta K.J.
VCaP, a cell-based model system of human prostate cancer.
In Vivo 15:163-168(2001)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=21698104; DOI=10.1371/journal.pone.0020874
Sfanos K.S., Aloia A.L., Hicks J.L., Esopi D.M., Steranka J.P., Shao W., Sanchez-Martinez S., Yegnasubramanian S., Burns K.H., Rein A., De Marzo A.M.
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines.
PLoS ONE 6:E20874-E20874(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23447416; DOI=10.1002/path.4186
Weier C., Haffner M.C., Mosbruger T.L., Esopi D.M., Hicks J.L., Zheng Q.-Z., Fedor H., Isaacs W.B., De Marzo A.M., Nelson W.G., Yegnasubramanian S.
Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.
J. Pathol. 230:174-183(2013)

PubMed=23615946; DOI=10.1007/s00439-013-1308-1
Teles Alves I., Hiltemann S., Hartjes T., van der Spek P.J., Stubbs A., Trapman J., Jenster G.
Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line.
Hum. Genet. 132:709-713(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28145883; DOI=10.18632/oncotarget.14850
Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M.-Q., Roshan-Moniri M., Butler M., Lehman M., Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C., Gleave M.E., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Oncotarget 8:18949-18967(2017)

PubMed=30305041; DOI=10.1186/s12885-018-4848-x
Jividen K., Kedzierska K.Z., Yang C.-S., Szlachta K., Ratan A., Paschal B.M.
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.
BMC Cancer 18:960.1-960.20(2018)

PubMed=30244336; DOI=10.1007/s00345-018-2501-6
Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F.
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
World J. Urol. 37:1117-1126(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=34402095; DOI=10.1002/pros.24210
Haffner M.C., Bhamidipati A., Tsai H.K., Esopi D.M., Vaghasia A.M., Low J.-Y., Patel R.A., Guner G., Pham M.-T., Castagna N., Hicks J.L., Wyhs N., Aebersold R., De Marzo A.M., Nelson W.G., Guo T.-N., Yegnasubramanian S.
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Prostate 81:1159-1171(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)